Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure

Posted On: 2020-11-23 01:50:32 (Time Zone: Arizona, USA)


The oral antiviral medication Favipiravir, that prevents the replication phase of the virus life-cycle, leads to significant improvement in clinical cure in patients with mild to moderate COVID-19. These findings were observed in a randomized, controlled Phase 3 clinical study conducted by Glenmark Pharmaceuticals, and the results are now published online in The International Journal of Infectious Diseases (IJID). The IJID is a globally reputed, peer-reviewed, pubmed indexed, open access journal published monthly by the International Society for Infectious Diseases, USA. The published findings will also appear in the print edition of the journal in the coming weeks.

The publication on the study titled "Efficacy and Safety of Favipiravir, an Oral RNADependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial" was authored by Dr. Zarir .F. Udwadia and other co-authors.

The link to the article is mentioned below

https://authors.elsevier.com/sd/article/S1201-9712(20)32453-X

https://www.sciencedirect.com/science/article/pii/S120197122032453X

The Phase 3 study with antiviral drug Favipiravir, brand name FabiFlu®, was conducted in 150 patients as part of a randomised, open label, multicenter, Phase 3 study. The study aimed to evaluate the efficacy and safety of Favipiravir plus standard supportive care (Favipiravir treatment arm), versus standard supportive care alone (control arm), in mild to moderate patients, randomized within a 48 hour window of testing RT-PCR positive for COVID-19.

Favipiravir was found to provide multiple treatment benefits, demonstrated by faster time to clinical cure, and significantly delayed the need for supportive oxygen therapy. Additionally, patients of confirmed COVID-19 with moderate symptoms were discharged from hospital earlier than those patients that did not receive Favipiravir, with the median time to clinical cure reduced by 2.5 days compared with the control group.

Dr Zarir F. Udwadia. MD, FRCP, FCCP, Breach Candy Hospital, Mumbai commented "Every claim for the efficacy of a new drug in COVID-19 must be backed by evidence from a clinical trial. Glenmark has done just that with Favipiravir. Their well-designed trial in 150 patients showed Favipiravir resulted in a significantly improved time to clinical cure and rapid viral clearance. Based on this I would consider the use of this anti-viral drug in symptomatic patients with mild to moderate COVID-19. I eagerly await the results of similar trials presently being conducted in Boston and at Stanford".

Since it was first pronounced a pandemic by the WHO in March, COVID-19 has continued to impact the lives of millions of people globally. As of date, over 50 mn. cases have been reported, with over 1 mn. deaths attributed to this disease. The virus has reportedly spread to all around the world and territories across the globe.i Most disease cases are mild to moderate, with symptoms including fever, cough and breathlessness. In severe cases, COVID-19 can cause pneumonia, severe acute respiratory syndrome, kidney failure and death.ii

Favipiravir is an antiviral medication that works by inhibiting a viral enzyme called RdRP (RNA dependent RNA polymerase), thereby halting the virus's replication cycle. This helps control the multiplication of the virus and prevents its spread in the patient. This mechanism of action of Favipiravir is novel compared to most antivirals that primarily prevent entry and exit of the virus from cells. Several published reports are now available of the drug's effectiveness against COVID-19.

Mr. Robert Crockart, Chief Commercial Officer Glenmark Pharmaceuticals said, "From the first reported case of COVID-19, our every effort was to bring a viable, safe and effective treatment option to patients in a timely manner. It is encouraging to see our trial results now published in a reputed global medical journal, which we hope will support other countries in their fight against this disease."

Patients in the Glenmark clinical trial received Favipiravir tablets 3,600 mg (1,800 mg BID) (Day 1) + 1,600 mg (800 mg BID) (Day 2 or later) for up to maximum of 14 days, along with standard supportive care. Randomization was stratified based on disease severity into mild and moderate. Favipiravir was well tolerated with no serious adverse events (SAEs) or deaths in the Favipiravir treated arm.

The pre-specified primary endpoint, time from randomisation to cessation of oral shedding of the SARS-CoV-2 virus, demonstrated a 2 day earlier virological cure in the Favipiravir treatment group, though not statistically significant. However, significant improvement in time to clinical cure and other secondary end-points suggest Favipiravir may be beneficial in the treatment of mild-to-moderate COVID-19.

"The study, which was undertaken by Glenmark Pharmaceuticals, at a time when the number of cases for infections were dramatically increasing around the globe, demonstrates Glenmark's commitment to ensuring all patients have access to affordable medication, to make a positive impact on their quality of life," said Dr. Monika Tandon, Sr. Vice President & Head - Clinical Development, Global Specialty/Branded Portfolio at Glenmark.

In June 2020, Glenmark received manufacturing and marketing approval from India's drug regulator for Favipiravir (FabiFlu®), making it the first oral approved medication in India for the treatment of mild to moderate COVID-19. The manufacturing and marketing approval was granted as part of an accelerated approval process, considering the emergency situation of the COVID-19 outbreak in India. The approval's restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.481.45 as compared to the previous close of Rs. 482.7. The total number of shares traded during the day was 69677 in over 1989 trades.

The stock hit an intraday high of Rs. 486.6 and intraday low of 478.3. The net turnover during the day was Rs. 33565841.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Welspun Specialty Solutions Ltd receives remibursement of power subsidy of Rs. 9.09 crore

Indian Bank board to consider fund raising on Jan 22, 2021

ICICI Lombard General Insurance Company Limited reports Q3FY21 earnings

JSW Ispat Special Products Ltd Q3FY21 consolidated net profit at Rs. 29.93 crore

Tata Steel BSL Ltd Q3FY21 consolidated net profit at Rs. 913.19 crore

Larsen & Toubro Infotech Ltd Q3FY21 consolidated PAT at Rs. 518.7 crore

Skipper Ltd reports consolidated net profit of Rs. 11.45 crore in Q3FY21

TV18 Broadcast Ltd reports consolidated PAT of Rs. 213.65 crore in Q3FY21

First tranche of Rs. 26.10 crore received by Prince Pipes from Prince Marketing

Infosys Builds applied AI Cloud, part of Infosys Cobalt

Tata Consumer Products recognized for its sourcing practices at CII Food Future Foundation (FFF) for Sustainable Sourcing 2020

NMDC Receives Platinum Award in Metal & Mining for Shiksha Sahayog Yojana

Adani and TOTAL deepen their strategic alliance in Sustainable Energy

Tata Communications Ltd Q3FY21 consolidated net profit at Rs. 309.15 crore

Medicamen Biotech Ltd to upgrade Bhiwadi plant as per CGMP norms

DCM Shriram Ltd board declares interim dividend of Rs. 5.50

Hatsun Agro Product Ltd updates on status of CAPEX projects

Vardhman Special Steels Ltd Q3FY21 net profit soars to Rs. 21.66 crore

CEAT Ltd Q3FY21 consolidated net profit at Rs. 132.14 crores

TATA Metaliks Ltd Q3FY21 net profit at Rs. 75.18 crore

DCM Shriram Ltd posts jump in Q3FY21 consolidated PAT to Rs. 252.55 crore

Alembic Pharmaceuticals Ltd Q3FY21 consolidated PAT of Rs. 292.57 crore

Hatsun Agro Product Ltd posts net profit of Rs. 67.31 crore in Q3FY21

Wardwizard Innovations & Mobility Limited Q3 net profit at Rs. 0.74 crore

Mold-Tek Packaging Ltd Q3 consolidated PAT higher at Rs. 14.93 crore

Gateway Distriparks Ltd Q3FY21 consolidated net profit surges to Rs. 32.74 crore

Nibe Limited enters into MOU with BEL Optronic Devices Ltd

HT Media Ltd posts consolidated PAT of Rs. 3.26 crore in Q3

Bank of Maharashtra Q3 consolidated PAT at Rs. 154.48 crore

Adani signs concession agreement with AAI for three airports

Thomas Cook India opens franchise - Gold Circle Partner - outlet in Gandhinagar

Eurocor Tech GmbH launches innovative long-length sizes further optimizing its peripheral Drug coated balloon system Freeway™ 035

BHEL wins Institute of Chartered Accountants of India's National Award 2019-20 for Excellence in Financial Reporting

Steel Strips Wheels Ltd bags export order for over 37,000 wheels

Escorts Ltd becomes first company to get Budni Certification in India for Electric Tractor

Man Industries India Limited receives news orders of Rs. 250 crores

CSB Bank Q3FY21 PAT at Rs. 53.05 crore

Dhruv Consultancy Services Limited receives LOA for consultancy services

L&T Finance Holdings Limited board approves 17:74 rights issue at Rs. 65 per share

'VISION 2025' Unveiled: Trident Limited announces Strategic Steps for Future Growth

Indiabulls Real Estate Ltd Q3FY21 consolidated net profit at Rs. 80.58 crore

ALOK Industries Ltd Q3 consolidated loss at Rs. 35.12 crore

Hindustan Media Ventures Ltd Q3FY21 consolidated net profit at Rs. 35.19 crore

Max Superspeciality Hospital Patparganj inaugurates its first neurosciences OPD in Rudrapur.

Kamdhenu Group Launched its Premium Product 'Kamdhenu Nxt' in Delhi and Haryana

Newgen Launches OmniDocs ActiveScript to Rapidly Automate Document-centric Processes

Aditya Vision Limited opens two new showrooms

Maruti Suzuki India Ltd to increase price of select models from Jan 18, 2021

JMT Auto Ltd to sell assets

Sagarsoft India Ltd Q3FY21 net profit at Rs. 1.37 crore



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020